Literature DB >> 208079

Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs.

C R Alving, E A Steck, W L Chapman, V B Waits, L D Hendricks, G M Swartz, W L Hanson.   

Abstract

Liposomes containing antimonial compounds trapped in the aqueous phase were tested in the treatment of experimental leishmaniasis. The rationale of this approach was based on the hypothesis that the liposomes and the parasite are taken up by the same cell, the reticuloendothelial cell, and we present electron microscopic evidence that supports this hypothesis. Suppression of leishmaniasis was quantified by determining the total number of parasites per liver from impression smears. When two antimonials, meglumine antimoniate and sodium stibogluconate, were encapsulated within liposomes, each was more than 700 times more active compared to either of the free (unencapsulated) drugs. After infection, if untreated, all of the hamsters eventually would die from the disease. Liposome-encapsulated meglumine antimoniate was about 330-640 times more effective in causing a drop in the death rate than was the free antimonial. The efficacy of treatment was influenced by the lipid composition and charge of the liposomes. For example, positively charged liposomes containing egg phosphatidylcholine were much less effective than negatively charged ones. In contrast, positively and negatively charged sphingomyelin liposomes were equally effective. Liposomes containing phosphatidylserine (which were negatively charged, but also had a much higher charge density) were among the less-effective preparations. Among those tested, the most consistently efficacious liposomes contained highly saturated long-chain phospholipids (eg., dipalmitoyl phosphatidylcholine), cholesterol, and a negative charge. We conclude that liposomes may be useful as carriers of drugs to treat infectious diseases involving the reticuloendothelial system. The toxicities of antimony are very similar to those of arsenic. Encapsulation of antimonial drugs and reduction of the dose required for effective therapy should minimize such systemic toxicities as acute cardiomyopathy and toxic nephritis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 208079      PMCID: PMC392686          DOI: 10.1073/pnas.75.6.2959

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  Algorithms in the diagnosis and management of exotic diseases. XXIV. Leishmaniases.

Authors:  A A Mahmoud; K S Warren
Journal:  J Infect Dis       Date:  1977-07       Impact factor: 5.226

2.  Antileishmanial activity of antimonials entrapped in liposomes.

Authors:  R R New; M L Chance; S C Thomas; W Peters
Journal:  Nature       Date:  1978-03-02       Impact factor: 49.962

3.  Dopaminergic pathway and prolactin: effect of a liposomal preparation.

Authors:  P Masturzo; A Gallamini; G Murialdo; M C Nizzo; G Toffano
Journal:  N Engl J Med       Date:  1977-08-11       Impact factor: 91.245

Review 4.  New aspects of liposomes.

Authors:  D A Tyrrell; T D Heath; C M Colley; B E Ryman
Journal:  Biochim Biophys Acta       Date:  1976-12-14

Review 5.  The carrier potential of liposomes in biology and medicine (second of two parts).

Authors:  G Gregoriadis
Journal:  N Engl J Med       Date:  1976-09-30       Impact factor: 91.245

6.  Liposomes as drug carriers.

Authors:  J H Fendler; A Romero
Journal:  Life Sci       Date:  1977-04-01       Impact factor: 5.037

7.  Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonial drug.

Authors:  C R Alving; E A Steck; W L Hanson; P S Loizeaux; W L Chapman; V B Waits
Journal:  Life Sci       Date:  1978-03       Impact factor: 5.037

8.  Testing of drugs for antileishmanial activity in golden hamsters infected with Leishmania donovani.

Authors:  W L Hanson; W L Chapman; K E Kinnamon
Journal:  Int J Parasitol       Date:  1977-12       Impact factor: 3.981

9.  [Phagocytosis of liposomes by mouse peritoneal macrophages (author's transl)].

Authors:  L Mattenberger-Kreber; G Auderset; M Schneider; A Louis-Broillet; M S Benedetti; A Malnoë
Journal:  Experientia       Date:  1976-12-15

10.  Liposome toxicity in the mouse central nervous system.

Authors:  D H Adams; G Joyce; V J Richardson; B E Ryman; H M Wiśniewski
Journal:  J Neurol Sci       Date:  1977-03       Impact factor: 3.181

View more
  45 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.

Authors:  Roma Sinha; Jayeeta Roychoudhury; Partha Palit; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

3.  Effect of liposome-entrapped ampicillin on survival of Listeria monocytogenes in murine peritoneal macrophages.

Authors:  I A Bakker-Woudenberg; A F Lokerse; J C Vink-van den Berg; F H Roerdink; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

4.  Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels.

Authors:  Raghavendra S Navath; Yunus E Kurtoglu; Bing Wang; Sujatha Kannan; Robert Romero; Rangaramanujam M Kannan
Journal:  Bioconjug Chem       Date:  2008-12       Impact factor: 4.774

Review 5.  Nanomedicines in gastroenterology and hepatology.

Authors:  Alf Lamprecht
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-10       Impact factor: 46.802

Review 6.  Liposomes as drug delivery system in the treatment of infectious diseases. Potential applications and clinical experience.

Authors:  A Coune
Journal:  Infection       Date:  1988 May-Jun       Impact factor: 3.553

7.  Treatment of experimental salmonellosis in mice with streptomycin entrapped in liposomes.

Authors:  T Tadakuma; N Ikewaki; T Yasuda; M Tsutsumi; S Saito; K Saito
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

Review 8.  Liposomal drug formulations. Rationale for development and what we can expect for the future.

Authors:  T M Allen
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

9.  Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice.

Authors:  Swati Pal; Rajesh Ravindran; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Suppression of both antimony-susceptible and antimony-resistant Leishmania donovani by a bis(benzyl)polyamine analog.

Authors:  R J Baumann; W L Hanson; P P McCann; A Sjoerdsma; A J Bitonti
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.